Oruka Therapeutics Publishes Presentation on ORKA-001 Phase 2b Psoriasis Trial Results
Bitget2026/10/26 12:12- Oruka Therapeutics published its EVERLAST-B interim data presentation on the Phase 2b psoriasis trial of ORKA-001.
- The 600 mg group achieved 61% PASI 100 and 86% PASI 90 response rates at Week 16.
- The 600 mg dose is planned for Phase 3, with initiation expected in the first half of 2027.
- No serious or severe treatment-emergent adverse events occurred in the high-dose group.
- Week 52 EVERLAST-A data are expected in December 2026 to support evaluation of annual dosing potential.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip giant makes a move in the quantum track: Intel (INTC.US) acquires startup Classiq to build a full-stack quantum business
Intel has announced the acquisition of Israeli quantum startup Classiq for an undisclosed amount, with the deal expected to be completed in the first half of 2027. Liwu Chen stated that they will develop a full-stack quantum computing business.
$17 billion acquisition emerges: DoorDash (DASH.US) in advanced talks to acquire Instacart, official announcement expected as early as this week
DoorDash plans to acquire Instacart's parent company Maplebear for approximately $17 billions, with an official announcement expected as early as this week. Maplebear shares rose 7.9%, while DoorDash fell 6.1%. The negotiations may fall through.
Fed and ECB decisions fall a day apart for a Euro under 1.12
Strong demand for AI chip design! Cadence Design Systems (CDNS.US) Q3 revenue up 22% year-on-year, full-year guidance raised
Kongteng Electronics reported Q3 revenue of $1.633 billions, representing a year-on-year increase of 22%, higher than the $1.339 billions recorded in the same period last year.
Crypto prices
More
